Molecular markers for pediatric low-grade glioma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Pediatric low-grade gliomas (PLGG) are often driven by RAS/MAPK pathway alterations. Comprehensive molecular profiling is key for diagnosing and managing these brain tumors.
Area Of Science
- Neuro-oncology
- Pediatric oncology
- Molecular genetics
Background
- Pediatric low-grade gliomas (PLGG) represent a significant portion of childhood brain tumors.
- Recent advances have elucidated key molecular drivers, primarily activating alterations in the RAS/MAPK pathway.
- Understanding these genetic alterations is crucial for accurate diagnosis and prognosis.
Purpose Of The Study
- To review the critical genetic alterations in pediatric low-grade glioma.
- To highlight the diagnostic and therapeutic implications of these molecular findings.
- To emphasize the importance of comprehensive molecular profiling in PLGG management.
Main Methods
- Review of current scientific literature on PLGG genetics.
- Analysis of key genetic alterations including fusions, point mutations, and copy number variations.
- Focus on genes such as BRAF, FGFR1, NF1, TP53, ATRX, and CDKN2A.
Main Results
- RAS/MAPK pathway alterations (BRAF, FGFR1, NF1) are the predominant drivers of PLGG.
- Second hits in tumor suppressor genes (TP53, ATRX, CDKN2A) can indicate more aggressive disease.
- Comprehensive genetic sequencing and copy number profiling are essential tools.
Conclusions
- Molecular profiling is indispensable for the classification and prognosis of PLGG.
- Identifying specific genetic alterations guides clinical management and therapeutic strategies.
- Continued research into PLGG molecular drivers will further refine treatment approaches.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.